L-半胱氨酸

L-半胱氨酸用途

面包改良剂；营养增补剂；抗氧化剂；护色剂。对丙烯腈和芳香族酸中毒有解毒作用；有预防放射线损伤作用；有治疗支气管炎和化痰作用；有吸收酒精，将其在体内转化为乙醛的解醉作用。
按GB 2760-96规定，准用于香料。
用于治疗湿疹、荨麻疹、雀斑等皮肤病，其系列产品广泛用于医药、食品和化妆品工业
用于生化研究，医药上用作肝炎、肝中毒、放射性药物中毒、锑剂中毒等的解毒剂。
广泛用于医药、食品化妆品等行业。
主要用于医药、化妆品、生化研究等方面。用于面包料中，以促进谷朊形成及促进发酵、出模、防止老化等。用于天然果汁中，以防止维生素C氧化和防止果汁变成褐色。该品有解毒作用，可用于丙烯腈中毒、芳香族酸中毒。该品还有预防放射线损伤人体的作用，也是治疗支气管炎的药物，尤其是作为化痰药（大多以乙酰L-半胱氨酸甲酯酸盐的形式使用。化妆品方面主要用于美容水、烫发液、防日晒的护肤膏霜等。

点击显示

L-半胱氨酸名称

[ CAS 号 ]:
52-90-4

[ 中文名 ]:
L-半胱氨酸

[ 英文名 ]:
L-cysteine

[中文别名 ]:

[英文别名 ]:

Cysteine
E 920
H-Cys-OH.Hcl
H-Cys-OH
L-2-Amino-3-mercaptopropionic acid
CYSH
L-Cysteine
3-mercapto-L-Alanine
L-Cys
b-Mercaptoalanine

L-半胱氨酸生物活性

[ 描述 ]:

L-半胱氨酸是含硫醇的非必需氨基酸,其被氧化形成胱氨酸。

[ 相关类别 ]:

天然产物 >> 酸和醛

研究领域 >> 代谢疾病

[ 靶点 ]

Human Endogenous Metabolite

[参考文献]

[1]. McGavigan AK, et al. L-cysteine suppresses ghrelin and reduces appetite in rodents and humans. Int J Obes (Lond). 2015 Mar;39(3):447-55.

[相关活性小分子]

L-半胱氨酸物理化学性质

[ 密度 ]:
1.3±0.1 g/cm3

[ 沸点 ]:
293.9±35.0 °C at 760 mmHg

[ 熔点 ]:
220 °C (dec.)(lit.)

[ 分子式 ]:
C₃H₇NO₂S

[ 分子量 ]:
121.158

[ 闪点 ]:
131.5±25.9 °C

[ 精确质量 ]:
121.019745

[ PSA ]:
102.12000

[ LogP ]:
0.23

[ 外观性状 ]:
白色结晶粉末

[ 蒸汽压 ]:
0.0±1.3 mmHg at 25°C

[ 折射率 ]:
1.550

[ 储存条件 ]:
存放于惰性气体之中;避免光,空气

[ 水溶解性 ]:
280 g/L (25 ºC)

L-半胱氨酸MSDS

详细MSDS(安全技术说明书)

L-半胱氨酸毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: HA1600000

CHEMICAL NAME :: Cysteine, L-

CAS REGISTRY NUMBER :: 52-90-4

LAST UPDATED :: 199710

DATA ITEMS CITED :: 31

MOLECULAR FORMULA :: C3-H7-N-O2-S

MOLECULAR WEIGHT :: 121.17

WISWESSER LINE NOTATION :: QVYZ1SH

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1890 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Kidney, Ureter, Bladder - other changes in urine composition

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1620 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1550 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1140 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 660 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1400 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1360 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1250 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 150 gm/kg/30D-C

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Behavioral - muscle weakness Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 308 gm/kg/26W-I

TOXIC EFFECTS :: Cardiac - other changes Lungs, Thorax, or Respiration - other changes Kidney, Ureter, Bladder - other changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 90 gm/kg/30D-C

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - other changes Endocrine - other changes Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 100 mg/kg

SEX/DURATION :: female 12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 3600 mg/kg

SEX/DURATION :: female 7-12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - physical

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 27600 mg/kg

SEX/DURATION :: female 23 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - menstrual cycle changes or disorders

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 6 gm/kg

SEX/DURATION :: male 30 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands

MUTATION DATA

TYPE OF TEST :: Sister chromatid exchange

TEST SYSTEM :: Rodent - hamster Ovary

DOSE/DURATION :: 100 umol/L

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 68,351,1979 *** REVIEWS *** TOXICOLOGY REVIEW DPIRDU Dangerous Properties of Industrial Materials Report. (Van Nostrand Reinhold, 115 Fifth Ave., New York, NY 10003) V.1- 1981- Volume(issue)/page/year: 3(1),14,1983 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-RUSSIA:STEL 2 mg/m3 JAN 1993 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4773 No. of Facilities: 81 (estimated) No. of Industries: 2 No. of Occupations: 7 No. of Employees: 8402 (estimated) No. of Female Employees: 7734 (estimated)

点击显示

L-半胱氨酸安全信息

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xn:Harmful

[ 风险声明 (欧洲) ]:
R22;R36/37/38

[ 安全声明 (欧洲) ]:
S36-S37/39-S26

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ RTECS号 ]:
HA1600000

[ 海关编码 ]:
2930901000

L-半胱氨酸合成路线

详细合成路线

L-半胱氨酸上下游产品

L-半胱氨酸上游产品

L-半胱氨酸下游产品

L-半胱氨酸制备

1.锡粒还原法将胱氨酸溶于稀盐酸中，过滤，滤液加入锡粒升温回流2h。将还原液用水稀释，移去剩余锡粒，通入硫化氢使饱和，过滤，滤渣用少量水洗，将洗、滤液合并，减压浓缩，冷却结晶，过滤、干燥得L-半胱氨酸盐酸盐。2.电解还原法将蒸馏水、盐酸、胱氨酸加入电解槽搅拌溶解，维持在50℃以下电解至终点。将所得电解液通硫化氢数小时，过滤。滤液加活性炭脱色，过滤后减压浓缩，冷却结晶，过滤，干燥，得L-半胱氨酸盐酸盐。
以L-半胱氨酸盐酸盐为原料，碱中和精制而得
由头发(或动物毛、羽)用盐酸加热6～8h，进行水解，经减压蒸馏馏出盐酸，加活性炭脱色、过滤，滤液用氨中和后得L-胱氨酸粗结晶，再用氨水液溶解并中和，经重结晶后，再用盐酸溶解并进行电解还原，然后浓缩、冷却、结晶、干燥而得。

点击显示

L-半胱氨酸海关

[ 海关编码 ]: 2930909090

[ 中文概述 ]:
2930909090. 其他有机硫化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2930909090. other organo-sulphur compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

L-半胱氨酸文献

Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.

Drug Des. Devel. Ther. 9 , 1555-84, (2015)

Osteosarcoma (OS) is the most common malignant bone tumor occurring mostly in children and adolescents between 10 and 20 years of age with poor response to current therapeutics. Alisertib (ALS, MLN823...

The unique regulation of iron-sulfur cluster biogenesis in a Gram-positive bacterium.

Proc. Natl. Acad. Sci. U. S. A. 111(22) , E2251-60, (2014)

Iron-sulfur clusters function as cofactors of a wide range of proteins, with diverse molecular roles in both prokaryotic and eukaryotic cells. Dedicated machineries assemble the clusters and deliver t...

Pharmacological inhibition of dynamin II reduces constitutive protein secretion from primary human macrophages.

PLoS ONE 9(10) , e111186, (2014)

Dynamins are fission proteins that mediate endocytic and exocytic membrane events and are pharmacological therapeutic targets. These studies investigate whether dynamin II regulates constitutive prote...

更多文献

L-半胱氨酸

L-半胱氨酸用途

L-半胱氨酸名称

L-半胱氨酸生物活性

L-半胱氨酸物理化学性质

L-半胱氨酸MSDS

详细MSDS(安全技术说明书)

L-半胱氨酸毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

L-半胱氨酸安全信息

L-半胱氨酸合成路线

详细合成路线

L-半胱氨酸上下游产品

L-半胱氨酸上游产品

L-半胱氨酸下游产品

L-半胱氨酸制备

L-半胱氨酸海关

L-半胱氨酸文献

相关化工产品/化学物质：

相关药品：

推荐生产厂家/供应商：

相关化合物